EDGAR Filing Documents for 0001144204-17-014561

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:

SEC Accession No. 0001144204-17-014561

Filing Date

2017-03-14

Accepted

2017-03-14 17:30:13

Documents

Period of Report

2016-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 10-Q	v459884_10q.htm	10-Q	471853
2	EXHIBIT 31.1	v459884_ex31-1.htm	EX-31.1	12298
3	EXHIBIT 31.2	v459884_ex31-2.htm	EX-31.2	12248
4	EXHIBIT 32.1	v459884_ex32-1.htm	EX-32.1	3829
5	EXHIBIT 32.2	v459884_ex32-2.htm	EX-32.2	3888
	Complete submission text file	0001144204-17-014561.txt		3958766

Data Files

Seq	Description	Document	Type	Size
6	XBRL INSTANCE DOCUMENT	rasp-20161231.xml	EX-101.INS	921744
7	XBRL TAXONOMY EXTENSION SCHEMA	rasp-20161231.xsd	EX-101.SCH	36562
8	XBRL TAXONOMY EXTENSION CALCULATION LINKBASE	rasp-20161231_cal.xml	EX-101.CAL	21729
9	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE	rasp-20161231_def.xml	EX-101.DEF	216413
10	XBRL TAXONOMY EXTENSION LABEL LINKBASE	rasp-20161231_lab.xml	EX-101.LAB	268658
11	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	rasp-20161231_pre.xml	EX-101.PRE	258596

Mailing Address 420 LEXINGTON AVENUE 25TH FLOOR NEW YORK NY 10170

Business Address 420 LEXINGTON AVENUE 25TH FLOOR NEW YORK NY 10170 212-398-4627

Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)